UMC Ljubljana

Medtronic's MiniMed 780G System Shows Promise for Type 2 Diabetes and Young Children with Type 1 Diabetes

- Medtronic's MiniMed 780G automated insulin delivery system demonstrated significant improvements in glycemic control for adults with insulin-intensive type 2 diabetes, achieving 84.9% time in range and reducing HbA1c from 7.7% to 6.9%. - The LENNY trial published in The Lancet Diabetes & Endocrinology showed young children aged 2-6 years with type 1 diabetes achieved 0.6% lower HbA1c and 9.9% higher time in range compared to manual mode. - Parents and caregivers reported improved sleep quality and reduced fear of hypoglycemia when children used the system's auto mode, highlighting the technology's impact on family quality of life. - The American Diabetes Association's 2025 Standards of Care now endorse automated insulin delivery systems for adults with insulin-intensive type 2 diabetes, validating the expanding role of diabetes technology.